# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates Armata Pharmaceuticals (AMEX:ARMP) with a Buy and maintains $7 p...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Armata Pharmaceuticals (AMEX:ARMP) with a Buy and maintains $7 p...
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate o...
HC Wainwright & Co. analyst Joseph Pantginis maintains Armata Pharmaceuticals (AMEX:ARMP) with a Buy and maintains $7 pr...
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate o...
The gross proceeds to be received by the Company at closing are $35 million before deducting transaction-related expenses. Proc...